GlassScriptPhysician profile
Srinivas Murali
NPI 1316921877
$39,487.65
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,216 · 2021: $4,846 · 2022: $8,636 · 2023: $6,215 · 2024: $14.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Consulting Fee: $2,160 · Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Consulting Fee | $2,159.50 |
| Food and Beverage | $169.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,050.00 | 2021-2023 | Jardiance |
| Pfizer INC. | $7,784.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $5,915.99 | 2019-2020 | |
| Lilly USA, LLC | $5,500.00 | 2021-2023 | Jardiance |
| Impulse Dynamics (USA) INC. | $3,166.00 | 2020-2024 | Optimizer, Optimizer |
| W. L. Gore & Associates, INC. | $2,159.50 | 2023 | Product In Development |
| Akcea Therapeutics, INC. | $1,590.00 | 2020 | |
| Medtronic, INC. | $1,546.19 | 2022 | |
| Medtronic Vascular, INC. | $667.91 | 2019 | |
| Abbott Laboratories | $258.43 | 2019-2022 | |
| Boston Scientific Corporation | $205.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $135.55 | 2019-2020 | |
| Amgen INC. | $112.98 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $89.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $75.59 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $66.57 | 2023 | Inpefa |
| Novo Nordisk INC | $39.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.16 | 2019-2020 | |
| Heartflow, INC. | $32.96 | 2023 | Ffrct |
| Sensible Medical Innovations INC | $22.31 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.21 | 2019 | |
| Bracco Diagnostics INC. | $14.00 | 2021 | |
| United Therapeutics Corporation | $2.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Murali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.